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Hyperprolactinemia is the most common cause of hypogonadotropic anovulation and is one of the leading 
causes of infertility in women aged 25–34. Hyperprolactinemia has been proposed to block ovulation through 
inhibition of GnRH release. Kisspeptin neurons, which express prolactin receptors, were recently identified as 
major regulators of GnRH neurons. To mimic the human pathology of anovulation, we continuously infused 
female mice with prolactin. Our studies demonstrated that hyperprolactinemia in mice induced anovulation, 
reduced GnRH and gonadotropin secretion, and diminished kisspeptin expression. Kisspeptin administra-
tion restored gonadotropin secretion and ovarian cyclicity, suggesting that kisspeptin neurons play a major 
role in hyperprolactinemic anovulation. Our studies indicate that administration of kisspeptin may serve as 
an alternative therapeutic approach to restore the fertility of hyperprolactinemic women who are resistant or 
intolerant to dopamine agonists.
Introduction
Hyperprolactinemia is the most common cause of hypogonado-
tropic anovulation (WHO Group I) and represents a major etiology 
of infertility, with highest incidence in women aged 25–34 years (1). 
In men, hyperprolactinemia is also frequently associated with hypo-
gonadotropic hypogonadism. This gonadotropic deficiency has 
been proposed to result from direct suppression of prolactin (PRL) 
on gonadotrophin-releasing hormone (GnRH) release, but evidence 
supporting this mechanism has never been provided. PRL is synthe-
sized and secreted by the lactotrope cells of the pituitary, and high 
levels of circulating PRL are mainly caused by lactotroph adenomas, 
which account for approximately 40% of all pituitary tumors. Pulsa-
tile GnRH replacement can reverse hypogonadotropic hypogonad-
ism and infertility induced by hyperprolactinemia in women as well 
as men (2, 3), suggesting that PRL excess in humans affects hypo-
thalamic release of GnRH rather than directly affecting pituitary or 
gonad function. However, very few GnRH neurons in mice express 
PRL receptors (PRLRs) (4), suggesting that PRL exerts its actions 
on upstream neurons regulating the GnRH neuron. Because GnRH 
neurons are stimulated by kisspeptin (Kp) neurons (5, 6), which 
unequivocally express PRLR (7), we hypothesized that GnRH defi-
ciency resulting from hyperprolactinemia is caused by reduced Kp 
input, which is now considered to be a primary gatekeeper govern-
ing reproduction (8, 9). Here, we show that hyperprolactinemia in 
mice induces hypogonadotropic anovulation and diminished Kp 
expression and that peripheral Kp administration restores GnRH 
and gonadotropin secretion and ovarian cyclicity. Therefore, we sug-
gest that hyperprolactinemic women resistant or intolerant to dopa-
mine agonists could take advantage of this therapeutic approach as 
a treatment for their infertility.
Results and Discussion
To address the mechanism of hyperprolactinemic anovulation, 
we developed a hyperprolactinemic mouse model simulating the 
human pathology by inserting micropumps releasing PRL over 
a period of 28 days. Control animals had normal estrous cycles 
every 5 days, while PRL-treated mice were acyclic or had irregu-
lar cycles following their first estrous cycle (Figure 1A). Another 
group of mice receiving PRL for only the first 14 days showed 
a resumption of normal estrous cycles after cessation of PRL 
delivery (Supplemental Figure 1; supplemental material avail-
able online with this article; doi:10.1172/JCI63937DS1).
Consistent with our hypothesis, daily Kp injections commenc-
ing on day 8 of PRL treatment and continuing to day 28 restored 
cyclicity (Figure 1B). Histological sections of both ovaries from 
each female were analyzed for the number of corpora lutea, a 
reflection of ovulation rate (Figure 1C). PRL-treated females 
exhibited few or no corpora lutea (0.50 ± 0.34, n = 6) as compared 
with control animals (7.5 ± 0.6, n = 8). These results indicate a clear 
impairment of ovulation by elevated PRL. Remarkably, daily injec-
tions of Kp were able to restore the ovulation rate (7.8 ± 0.6, n = 
19) to that found in control females (Figure 1D). We have recently 
shown that Kp administration can restore luteinizing hormone 
(LH) pulsatility in neurokinin B–deficient patients, suggesting 
that the GnRH neuron sets up its own pulsatility when stimulated 
with Kp (10). This may explain the restoration by once-daily Kp in 
the hyperprolactinemic mice.
A set of mating experiments was performed to confirm that 
estrus took place. After introducing a fertile stud male mouse into 
the cage at the end of treatment, we recovered plugs in 3 of 4 PRL 
plus Kp–treated mice (data not shown), which is an index of suc-
cessful mating that leads to pregnancy (11). The female mouse 
copulates only during estrus, when ova are ready for fertilization.
The anovulation in PRL-treated mice was accompanied by a 
significant decrease in pituitary Lhb and follicle-stimulating hor-
mone β (Fshb) transcripts (Figure 2A) and serum LH and FSH 
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levels (Supplemental Figure 2), indicating a gonadotropin defi-
ciency, and this was reversed by Kp administration.
This suggests a deficiency in Gnrh gene expression and/or bio-
synthesis and/or GnRH peptide release. However, hypothalamic 
Gnrh gene expression was not altered in the 3 groups of mice (Fig-
ure 2B), as was reported in Kiss1-null mice (12, 13). To investigate 
whether GnRH release was impaired after PRL treatment and to 
test whether Kp could overcome this, we conducted a series of in 
vitro experiments using hypothalamic explants. We challenged 
medial basal hypothalamus (MBH) explants, including the 
median eminence, the arcuate nucleus, as well as the ventrome-
dial nucleus, with PRL followed by Kp. GnRH released into the 
culture medium was significantly inhibited during the second 
hour of exposure to PRL (Figure 2C). The addition of Kp (500 
nM) during the second hour of PRL treatment was able to restore 
GnRH secretion (Figure 2C). Our 
experiments therefore demonstrate 
the ability of PRL to inhibit the 
secretion of GnRH, and this seems 
to be mediated through decreased 
Kp secretion. These experiments 
aimed to avoid desensitization of 
the Kp receptor to continuous Kp 
exposure by limiting the periods 
of incubation (14). Overall, these 
data suggest that reduced Kp might 
mediate PRL inhibition of cycles 
but cannot completely exclude 
the possible involvement of other 
GnRH stimulators or inhibitors, or 
upstream regulators of Kp.
Since Kp reversed the inhibition 
of GnRH release and anovulation in 
PRL-treated female mice, we hypoth-
esized that anovulation is due to 
hypothalamic Kp decline. In support 
of this, we demonstrated a significant decrease of hypothalamic 
Kiss1 mRNA in PRL-treated mice (Figure 2D). The emerging view 
of Kp signaling is that it is responsible for two modes of GnRH 
secretion: the estrogen-induced ovulatory surge of GnRH/LH and 
basal pulsatile GnRH/LH release. In rodents, there are two popu-
lations of Kp neurons, one in the anteroventral-periventricular 
nucleus (AVPV) involved in positive feedback of sex steroids on 
the gonadotrope axis and the second one in the arcuate nucleus 
(ARC) involved in negative feedback (15). Here, we have evidence 
of a decrease in immunoreactive Kp in both the ARC and AVPV, 
suggesting the involvement of these two nuclei in hyperprolac-
tinemia-induced anovulation (Figure 2E). This contrasts with the 
opposing effects of sex steroids in the two regions (15). Recent 
studies suggest that the regulation of GnRH in ARC Kp neu-
rons is more complex, as this population of Kp neurons has been 
Figure 1
Effects of PRL infusion with daily injec-
tion of PBS or Kp on 6-week-old adult 
female mice. (A) Estrous cycle profiles 
of a single representative mouse from 
control, PRL, and PRL+Kp groups over 
28 days. Each stage of the estrous cycle 
was determined by daily vaginal smears. 
Lines under each diagram represent 
daily intraperitoneal injections of Kp or 
PBS as control in mice treated with PRL. 
(B) Mean cycle numbers during 21 days. 
PRL mice (n = 12) had significantly fewer 
cycles than control (n = 21) and Kp-treat-
ed mice (n = 19). ***P < 0.0001. (C) Rep-
resentative ovarian histological sections 
from each group. Asterisks indicate cor-
pora lutea, reflecting ovulation rate. (D) 
Mean number of corpora lutea in both 
ovaries at the end of the experiment. 
Analysis revealed a marked decrease in 
corpora lutea in the PRL group (n = 6) 
versus the control (n = 8) and PRL+Kp 
groups (n = 19). ***P < 0.0001.
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found to coexpress another neuromodulator implicated in the 
regulation of gonadotrope axis, neurokinin B (16, 17). Thus, we 
also measured Tac2 gene and protein (NKB) expression, which was 
not altered after PRL administration (Figure 2F and Supplemen-
tal Figure 3). The presence of PRL receptors on Kp neurons (5) 
together with the suppression of Kp mRNA and peptide expres-
sion and restoration of ovarian cyclicity by Kp administration 
in our study are supportive of a direct inhibitory action of PRL 
on Kp neurons as the most parsimonious explanation. However, 
other GnRH stimulators or inhibitors, or upstream regulators of 
Kp, might be involved in PRL inhibition of cycles.
The data presented here reveal that treatment with PRL alone 
is sufficient to decrease Kiss1 mRNA. Thus, the decrease in Kiss1 
mRNA levels found in the ARC and AVPV in rats during lacta-
tion (18, 19) is likely due to the increased PRL secretion during 
lactation. This had been uncertain in these previous studies, as 
there are many changes associated with lactation other than 
increased PRL. These include metabolic changes that have been 
shown to affect Kp and GnRH (15).
Together, these data are consistent with the hypothesis that 
the anovulation of hyperprolactinemia is mediated through PRL 
inhibition of Kiss1 gene expression and downstream diminution 
of GnRH and gonadotropin secretion. Kp neurons appear, there-
fore, to be the possible missing link between hyperprolactinemia 
and GnRH deficiency in mammals. Our findings suggest the pos-
sibility of therapeutic administration of Kp to hyperprolactin-
emic women who are resistant to dopamine agonists as a treat-
ment for infertility.
Methods
Mice and treatment. Six-week-old female mice were anesthetized with iso-
flurane inhalation. ALZET minipumps (model 2004) containing 200 
μg PRL (National Hormone and Peptide Program [NHPP] AFP10692C, 
provided by A. Parlow, NIDDK, Harbor-UCLA Medical Center, Torrance, 
California, USA) or PBS (control group) were implanted s.c. between the 
scapulae as previously described (20). Minipumps delivered PRL at a rate 
of 7 μg/24 hours over 28 days. Pilot experiments established that the 
serum concentration of PRL was 260 ng/ml. Thirty-one mice were treated 
Figure 2
Effect of PRL on gene expression and Kp immunostaining and GnRH release, and effect of Kp on PRL inhibition of GnRH release. (A) Gene 
expression of pituitary Lhb and Fshb transcripts is decreased in PRL mice (n = 4) compared with control mice (n = 19) and increased in PRL+Kp 
mice (n = 8). **P < 0.01, *P < 0.05. (B) Gene expression of hypothalamic Gnrh transcripts is not altered among all 3 groups: control (n = 27), PRL 
(n = 10), and PRL+Kp mice (n = 10). (C) PRL inhibition of GnRH release from hypothalamic explants is reversed by 500 nM Kp. n = 10 for each 
group. **P < 0.01, *P < 0.05; see Methods for details. (D) Gene expression of Kiss1 transcripts is significantly decreased in PRL-treated (n = 10) 
compared with control (n = 26) mice. **P < 0.01. (E) Representative of 6 independent experiments. Kiss neurons staining in ARC and AVPV sec-
tions from control and PRL-treated mice. Scale bars: 50 μm. (F) Gene expression of hypothalamic Tac2 transcripts is not altered in the PRL-treated 
group of mice (n = 8) compared with the control group (n = 18).
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with PRL over 28 days, and 4 received PRL for only 14 days and were then 
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by Bachem Distribution Service GmBH) commencing after 8 days of PRL 
treatment. Mice were sacrificed and tissues removed, weighed, and stored 
for subsequent gene expression and histological analyses.
Analysis of estrous cyclicity. Estrous cycles were monitored by vaginal 
smears taken at the same time daily over 28 days and analyzed for the pre-
dominance of either lymphocytes, or nucleated epithelial cells or keratino-
cytes. One drop of PBS from a Pasteur pipette was expelled into the vagina, 
aspired, and then transferred to a microscope slide.
Histological studies. Ovaries were dissected and fixed for 5 hours in 4% PFA, 
washed, paraffin-embedded, and sectioned at 3–4 μm. Tissue sections were 
analyzed after hematoxylin and eosin staining.
Immunohistochemistry. Ten mice were anesthetized with intraperitoneal 
injection of pentobarbital and perfused through the heart first with saline 
(0.9% NaCl) and then with 15 ml 4% PFA in PBS over 9 minutes. The brains 
were removed, and pituitaries, hypothalami, and ovaries were dissected out 
and immersed in 15% aqueous sucrose solution (2% PFA, 15% sucrose in 
PBS) overnight. The tissues were stored in 30% sucrose in PBS, 0.02% sodi-
um azide. Coronal brain sections (40 μm thickness) were cut on a freezing 
microtome and collected from the diagonal band of Broca (DGB) to the 
mammillary bodies. Free-floating sections were permeabilized in PBS/Tri-
ton X-100 (0.3%), followed by 10 minutes of heat-induced epitope retrieval 
in a microwave using 10 mM citrate buffer (pH6). Endogenous peroxidases 
were quenched using 0.3% H2O2 in PBS (25 minutes), and sections were 
blocked for 1 hour at room temperature using 10% normal goat serum, 
PBS, and 5% BSA. Sections were then incubated overnight at 4°C using 
a highly specific Kp antibody (1:15,000) (21). Immunoreactive sites were 
visualized using an ABC kit (Vector Elite Kit PK6101, Vector Laboratories) 
and DAB chromogen (ImmPACT DAB, SK-4105, Vector Laboratories). 
Kp-immunoreactive neuron counts in both the AVPV and ARC were per-
formed in a blinded manner.
Gene expression analyses. Total RNA was extracted from pituitaries and 
hypothalami using TRIzol reagent (Invitrogen). Quantitative real-time 
PCR was performed as described previously (22). After DNAse I treatment 
(Invitrogen), RNA was reverse transcribed and used for quantitative RT-
PCR (qRT-PCR) using the Power SYBR Green PCR Master Mix (Applied 
Biosystems). Final primer concentrations were 300 nM for each primer 
(Supplemental Table 1 shows primer sequences). Reaction parameters were 
carried out on a StepOne Real-Time PCR System (Applied Biosystems). 
Reaction parameters were as follows: 95°C for 20 seconds, then 40 cycles 
at 95°C for 1 second and 60°C for 20 seconds. Controls without reverse 
transcriptase and without template were included to verify that fluores-
cence was not overestimated by residual genomic DNA amplification or 
from primer dimer formation. Moreover RT-PCR products were analyzed 
in a post-amplification melting curve to ensure that a single amplicon was 
obtained. Quantification was performed by the standard curve method. For 
preparation of standards, amplicons were purified from agarose gel and 
subcloned into a pGEM-T Easy plasmid (Promega), then sequenced to verify 
the identity of each fragment. Standard curves were generated by serial dilu-
tions, spanning 6 orders of magnitude, yielding a correlation coefficient 
of at least 0.98 in all experiments. For all experiments, PCR efficiency was 
close to 1, indicating a doubling of DNA at each PCR cycle, as expected. 
Ribosomal 18S was used as reference gene for data normalization. Relative 
expression of a given gene is expressed as the ratio of attomoles of specific 
gene to femtomoles of rRNA 18S. Results are mean ± SEM and represent 
the relative expression compared with that obtained with controls.
Hormone ELISA. For the LH ELISA, mouse LH (AFP5306A, NIDDK) was 
used as standard (range, 0.78–25 ng/ml), with anti–bovine LH chain mAb (2 
μg/ml; 518B7; gift from J. Roser, UCLA, Los Angeles, California, USA) used 
as capture antibody. The second antibody was biotinylated anti–human LH 
mAb (1 μg/ml; Medix Biochemica 5303), and Amdex streptavidin-HRP con-
jugate (1:10,000; GE Healthcare) RPN4401Vq was used for signal detection.
For the FSH ELISA, mouse FSH (NIDDK AFP5308D; provided by A. 
Parlow, Harbor-UCLA Medical Center, Torrance, California, USA) was used 
as standard (range, 0.78–50 ng/ml), with anti–human FSH mAb (4 μg/ml; 
Medix Biochemica 6602, BiosPacific Inc.) used as capture antibody. The 
second antibody was biotinylated rabbit anti–rat α-subunit IC1 (5 μg/ml; 
NIDDK AFP66P99860), and anti–rabbit HRP conjugate (1:10,000; Thermo 
Scientific 31458) was used for signal detection.
Study of GnRH release. To determine whether hyperprolactinemia acts 
through Kp on GnRH release, 30 hypothalami were dissected from 
untreated female mice, incubated individually in wells of a 48-well plate in 
250 μl DMEM (21047033, Invitrogen) saturated with 95% O2/5% CO2, and 
placed at 37°C in a 5% CO2 atmosphere cell culture incubator. Hypotha-
lamic explants from normal 10-week-old female mice were incubated for 1 
hour to acclimate them and then exposed to vehicle or 1 μg/μl of PRL for 
1 hour. In the third hour, explants were exposed to fresh vehicle or PRL, 
or PRL plus 500 nM Kp, and the medium was stored at –20°C for GnRH 
assay. The hypothalamic fragments were then challenged for 1 hour with 
60 mM KCl to elicit GnRH release to confirm functional viability of the 
tissue fragments. GnRH concentrations were determined by a specific RIA 
as previously described (23) using the BDS 037 antibody. The sensitivity 
averaged 2 pg/ml (10 assays), and intraassay and interassay coefficients of 
variation averaged 10% and 13%, respectively.
Statistics. Data are expressed as mean ± SEM. Mann-Whitney U test was 
used to determine significant differences between 2 groups. For multiple 
comparisons, Kruskal-Wallis test followed by Dunn’s post-test was per-
formed with the use of Prism 4 (GraphPad Software). P values less than 
0.05 were considered statistically significant.
Study approval. All procedures were approved by the Ministère de 
l’Agriculture, France.
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